Novo Nordisk launches world’s fastest acting insulin in Bangladesh
Danish pharma huge Novo Nordisk yesterday launched the world's speediest acting insulin on the Bangladesh market as the number of diabetic patients on the country is soaring fast amid fast urbanisation and change on lifestyle.
This fast-acting insulin will work four times quicker than short-acting human insulin and two-times quicker than the conventional rapid acting insulin.
It can be utilised in people with type-1 and type-2 diabetes, the company said in a assertion.
AK Azad Khan, president of the Diabetic Association of Bangladesh (BADAS), launched the brand new insulin at a good programme at Resort InterContinental in Dhaka and also other senior high-ups of the business.
The new insulin can be used during pregnancy and breast-feeding period, the statement said.
"People coping with diabetes often battle to control bloodstream glucose exclusively around mealtimes. This could be extremely challenging and could bring about devastating diabetes-related difficulties," Khan said.
The insulin can help patients achieve desired blood sugar level with less hypoglycaemia and various other diabetes-related complexities, he said.
Bangladesh had never experienced a shortage of insulin, as Novo Nordisk was first there in the united states since 1958, he said.
However, some people could not buy it due to their financial concerns, Khan added.
Around 50 per cent of diabetic patients are not diagnosed yet because they are not well aware of the issue, he added.
"I am really very happy to see that Novo Nordisk is performing a essential role in introducing study and development based impressive insulin for helping an incredible number of diabetic patients in the country," said Winnie Estrup Petersen, ambassador of Denmark to Bangladesh.
"I think that Novo Nordisk's native production facility provides further usage of quality insulin for clients," he added.
As part of the Diabetic Association of Bangladesh's awareness and prevention programme, Novo Nordisk is closely dealing with the association in creating nationwide awareness along with introducing ground breaking insulin, said Md Sayef Uddin, secretary general of BADAS.
"As a worldwide leader in diabetes health care, we are focused on introduce technology for the good thing about people living with diabetes found in Bangladesh," explained Mihail Briciu, managing director of Novo Nordisk Bangladesh.
"We are consistently researching innovative answers to improve diabetes operations and more innovative treatment plans are in the offing for people coping with diabetes in Bangladesh," Briciu said.
In conditions of diabetes maintenance systems, Novo Nordisk may be the number one in the world, he said.
The company is affiliated in 80 countries and it marketplaces its products to 170 countries.
Some 43,500 people around the globe now work for Novo Nordisk, which was established in 1923, he said.
Bangladesh may be the 10th most diabetes sufferer burdened country on the planet, he said.
One out of 11 adults had diabetes found in 2019, Mihail said, even while he was first presenting the keynote paper in the event.
He also said 8.3 million persons or 9.2 % of the adult people of Bangladesh possess diabetes and 4 million clients have been diagnosed by yesterday.
Some 15 million adults could have diabetes by 2045 plus some $535 million was spent treating diabetes in 2019, he said.
Novo Nordisk, together with Eskayef Pharmaceuticals, a respected pharmaceutical organization owned by Transcom Group, has been manufacturing insulin in Bangladesh since 2012. Transcom Distribution Enterprise distributes the insulin across the country.
Mohammad Mahbubur Rahman, brain of medical and top quality of Novo Nordisk; Md Tanbir Sajib, brain of professional affairs; Gazi Towhid Ahmed, public affairs supervisor, and Mezba Ul Gaffar, group product manager, were also present.
